<SEC-DOCUMENT>0001213900-22-024642.txt : 20220509
<SEC-HEADER>0001213900-22-024642.hdr.sgml : 20220509
<ACCEPTANCE-DATETIME>20220509060553
ACCESSION NUMBER:		0001213900-22-024642
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220509
FILED AS OF DATE:		20220509
DATE AS OF CHANGE:		20220509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		22903110

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea159579-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Month of May 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: 001-38104</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>IMMURON
LIMITED&nbsp;</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Level
3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia&nbsp;</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive office)</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&ldquo;Yes&rdquo; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXPLANATORY
NOTE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (the &ldquo;Company&rdquo;) published one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange
on May 9, 2022 titled:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#9;&ldquo;US
DoD Uniformed Services University Clinical Update&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A copy of the Public Notice is attached as an exhibit to this report on
Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report on Form 6-K (including the exhibit hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities
Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
 Number</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea159579ex99-2_immuron.htm">IMC - ASX Announcement US DoD Uniformed Services University Travelers Diarrhea Clinical Update May 2022 Ed1.00</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 9, 2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><IMG SRC="image_001.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 338pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>2
<FILENAME>ea159579ex99-2_immuron.htm
<DESCRIPTION>IMC - ASX ANNOUNCEMENT US DOD UNIFORMED SERVICES UNIVERSITY TRAVELERS DIARRHEA CLINICAL UPDATE MAY 2022 ED1.00
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.2</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-2_001.jpg" ALT=""></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US
Department of Defense Uniformed Services University Clinical Evaluation of Travelan&trade;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UPDATE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Points</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Manufacture Completed of investigational medical
products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the comparative
efficacy of Travelan&reg; with two third party non-antibiotic OTC products in Travelers&rsquo; Diarrhea</B></FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                            </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The treatment period in the clinical protocol
has been extended from 13 days to 22 days, to accommodate COVID-19 quarantine period requirements during travel</B></FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Initial shipments of investigational medicinal
products to clinical trial sites now dispatched</B></FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>USU are anticipating an enrolment start date
of June 2022 and plan to enrol 1336 participants in total</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Melbourne, Australia, May 09, 2022: Immuron Limited
(ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products
for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with a progress update on the
planned clinical trial to evaluate the efficacy of Travelan&reg; and two third party non-antibiotic products in Travelers&rsquo; Diarrhea</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">USU&rsquo;s Infectious Diseases Clinical Research
Program (IDCRP), the UK Ministry of Defense and the New York City Travel Clinic are jointly planning to conduct the randomized clinical
trial to evaluate the efficacy of three commercially available nutraceutical products for TD and inform strategies for Defense Force Health
Protection. The P4TD study is a randomized, double-blind, placebo controlled multicenter clinical trial designed to evaluate the effectiveness
of 3 nutraceuticals: A prebiotic (Bimuno&reg;), a probiotic (Florastor&reg;) and IMM-124E (Travelan&reg;) passive immunoprophylaxis verses
a placebo, for prophylaxis during deployment or travel to a high-TD risk region (ClinicalTrials.gov Identifier: NCT04605783)All study
participants (1336 in total) will be randomized to one of the three active products or placebo (334 per arm).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">USU have completed the manufacture of the first
batches of investigational medicinal products and shipment of these to the first clinical trial sites is now complete. USU are anticipating
recruitment of study participants to commence in June 2022 and expect to complete clinical trial enrolment in approximately 18 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The clinical protocol has also been amended to
extend the treatment period from 13 days to 22 days to cover the COVID-19 quarantine period still required by some countries. The extended
time is necessary as those travelers required to quarantine upon arrival who may be still at risk of diarrhea symptoms during this period.
The protocol amendment has now been submitted to the ethics board for approval and recruitment will commence once approval has been granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%">

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3, 62 Lygon Street,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carlton South, Victoria</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AUSTRALIA &nbsp;3053</P></TD>
    <TD STYLE="width: 33%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.immuron.com</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABN: 80 063 114 045</P></TD>
    <TD STYLE="width: 36%">

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phone: + 61 (0)3 9824 5254</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: + 61 (0)3 9822 7735</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1.5pt solid; text-align: right; width: 50%"><IMG SRC="ex99-2_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Problem: </B>Travelers&rsquo; diarrhea
(TD) remains a highly prevalent disease that impacts operational readiness of military personnel and is also debilitating civilian travel.
In addition to its acute morbidity, TD is associated with acquisition of antimicrobial resistance genes and long-term sequelae. Current
mitigation strategies including pre-travel counseling and antibiotics for prevention and treatment have important limitations, and there
are currently no licensed, pathogen-specific vaccines for TD prevention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Approach:</B> Prebiotics, probiotics and
passive immunotherapy may offer safe and relatively inexpensive preventive strategies by promoting gut resistance to enteropathogens,
and potentially lessening the use of antibiotics. USU&rsquo;s Infectious Diseases Clinical Research Program (IDCRP), the UK Ministry of
Defense and the New York City Travel Clinic are jointly conducting a randomized clinical trial to evaluate the efficacy of these nutraceutical
products for TD prevention and inform strategies for Force Health Protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release has been authorised by the directors
of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMPANY CONTACT:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dr Jerry Kanellos, Ph.D.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ph: +61 (0)3 9824 5254</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">info@immuron.com</P></TD>
    <TD STYLE="width: 37%; font-size: 10pt; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 31%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>About Immuron</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one
commercial asset generating revenue. In Australia, Travelan&reg; is a listed medicine on the Australian Register of Therapeutic Goods
(AUST L 106709) and is indicated to reduce the risk of Travellers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders
and is antimicrobial. In Canada, Travelan&reg; is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk
of Travellers&rsquo; Diarrhea. In the U.S., Travelan&reg; is sold as a dietary supplement for digestive tract protection in accordance
with section 403 (r)(6) of the Federal Drug Administration (FDA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Travelan&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelan&reg; is an
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea, <FONT STYLE="background-color: white">a
digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>. Travelan&reg; is a highly
purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia, Travelan&reg; is a listed
medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is a licensed natural health product
(NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S., Travelan&reg; is sold as a dietary supplement
for digestive tract protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 3</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1.5pt solid; text-align: right; width: 50%"><IMG SRC="ex99-2_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Travelers&rsquo; diarrhea</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelers&rsquo; diarrhea
is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating
and fever. Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli</I> (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with travelers&rsquo; diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">For more information
visit: http://www.immuron.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">Page 3 of 3</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ #H# 2(  A$! Q$!_\0
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MJO%<(UY-;EAYB -C_9/3]<U8/3BL/5[AM-U+3[XJ/(>3[+._=0WW#_WUQ^-
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G(0HS@!CD_K0!U0HH%% !1110 4444 %(0,]***  # P*6BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 10# 2(  A$! Q$!_\0
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MJ)!P1;2?^@FO#_A_$LOC72PR[@K,WXA2<U[AKG_(OZC_ ->LG_H)KQ3X<?\
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MB.1&IP /J<G\JSO'?B:\U[6)-'T_S7LX&V%(@29G'4G'4 \"NC^%-WGX60*
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0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  = %X# 2(  A$! Q$!_\0
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MYC K&(.TT@ZYST'^>:V/"&MWFK6=W;:FB+J-A.;>X*?=8CHP^M4? /(\0?\
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JA!VYX]ZOV&F_8Y99Y;J:ZN) %:67&0HS@    <G\Z4Y4VGRA!3TN?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
